EXEL
Price
$64.63Alerts
Change
-$1.20 (-1.82%)
Updated
Nov 20 closing price
Capitalization
17.24B
79 days until earnings call
Intraday BUY SELL Signals
REGN
Price
$920.69Alerts
Change
-$2.65 (-0.29%)
Updated
Nov 20 closing price
Capitalization
93.11B
68 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EXEL vs REGN

EXEL vs REGN Comparison Chart in %
View a ticker or compare two or three
VS
EXEL vs. REGN commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and REGN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EXEL with price predictions
Nov 20, 2026

EXEL in upward trend: price may jump up because it broke its lower Bollinger Band on November 19, 2026

EXEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 30 cases where EXEL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in 209 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

The Aroon Indicator entered an Uptrend today. In 176 of 278 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.

Bearish Trend Analysis

The 10-day RSI Indicator for EXEL moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 26 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 65%.

The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EXEL as a result. In 60 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.

The Moving Average Convergence Divergence Histogram (MACD) for EXEL turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 21 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.349) is normal, around the industry mean (3.596). P/E Ratio (21.146) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (6.305) is also within normal values, averaging (443.347).

A.I.Advisor
a Summary for REGN with price predictions
Nov 20, 2026

REGN in upward trend: 10-day moving average broke above 50-day moving average on October 26, 2026

The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 18, 2026. You may want to consider a long position or call options on REGN as a result. In 60 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.

REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 203 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 178 of 264 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.

Bearish Trend Analysis

The 10-day RSI Indicator for REGN moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 18 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 44%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 64 cases where REGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 59%.

The Moving Average Convergence Divergence Histogram (MACD) for REGN turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 26 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.936) is normal, around the industry mean (3.596). P/E Ratio (21.599) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.158). Dividend Yield (0.004) settles around the average of (131.631) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (443.347).

FUNDAMENTALS RATINGS
EXEL vs REGN: Fundamental Ratings
EXEL
REGN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
363
SMR RATING
1..100
2359
PRICE GROWTH RATING
1..100
374
P/E GROWTH RATING
1..100
2622
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (88) in the Biotechnology industry is in the same range as EXEL (90). This means that REGN’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's Profit vs Risk Rating (3) in the Biotechnology industry is somewhat better than the same rating for REGN (63). This means that EXEL’s stock grew somewhat faster than REGN’s over the last 12 months.

EXEL's SMR Rating (23) in the Biotechnology industry is somewhat better than the same rating for REGN (59). This means that EXEL’s stock grew somewhat faster than REGN’s over the last 12 months.

REGN's Price Growth Rating (4) in the Biotechnology industry is somewhat better than the same rating for EXEL (37). This means that REGN’s stock grew somewhat faster than EXEL’s over the last 12 months.

REGN's P/E Growth Rating (22) in the Biotechnology industry is in the same range as EXEL (26). This means that REGN’s stock grew similarly to EXEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELREGN
RSI
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
44%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
59%
Momentum
ODDS (%)
Bearish Trend 3 days ago
65%
Bullish Trend 3 days ago
65%
MACD
ODDS (%)
Bearish Trend 3 days ago
49%
Bearish Trend 3 days ago
54%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
57%
Bearish Trend 3 days ago
57%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
66%
Advances
ODDS (%)
Bullish Trend 14 days ago
68%
Bullish Trend 14 days ago
64%
Declines
ODDS (%)
Bearish Trend 3 days ago
57%
Bearish Trend 3 days ago
56%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
50%
Aroon
ODDS (%)
Bullish Trend 3 days ago
63%
Bullish Trend 3 days ago
67%
COMPARISON
Comparison
Nov 22, 2026
Stock price -- (EXEL: $64.63 vs. REGN: $920.69)
Brand notoriety: EXEL and REGN are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 69% vs. REGN: 93%
Market capitalization -- EXEL: $17.24B vs. REGN: $93.11B
EXEL [@Biotechnology] is valued at $17.24B. REGN’s [@Biotechnology] market capitalization is $93.11B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 3 FA rating(s) are green while REGN’s FA Score has 2 green FA rating(s).

  • EXEL’s FA Score: 3 green, 2 red.
  • REGN’s FA Score: 2 green, 3 red.
According to our system of comparison, EXEL is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 5 bullish TA indicator(s).

  • EXEL’s TA Score: 4 bullish, 4 bearish.
  • REGN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, REGN is a better buy in the short-term than EXEL.

Price Growth

EXEL (@Biotechnology) experienced а -6.33% price change this week, while REGN (@Biotechnology) price change was -3.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.

Reported Earning Dates

EXEL is expected to report earnings on Feb 09, 2027.

REGN is expected to report earnings on Jan 29, 2027.

Industries' Descriptions

@Biotechnology (-11.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with INCY. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then INCY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
-1.82%
INCY - EXEL
53%
Loosely correlated
-1.07%
MIRM - EXEL
47%
Loosely correlated
+0.65%
PTCT - EXEL
43%
Loosely correlated
-3.27%
ARQT - EXEL
40%
Loosely correlated
-2.98%
IMTX - EXEL
39%
Loosely correlated
-3.03%
More

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with RPRX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then RPRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-0.19%
RPRX - REGN
44%
Loosely correlated
+1.08%
VRTX - REGN
43%
Loosely correlated
-1.08%
EXEL - REGN
41%
Loosely correlated
-1.82%
INCY - REGN
40%
Loosely correlated
-1.07%
BMRN - REGN
35%
Loosely correlated
-1.64%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LXP61.18N/A
N/A
LXP Industrial Trust
INAC10.45N/A
N/A
INDIGO ACQUISITION CORP
CAPL19.62-0.30
-1.51%
CrossAmerica Partners LP
BTLN2.81-0.24
-7.87%
Brightline Interactive Inc
CLS201.80-38.43
-16.00%
Celestica